(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 646.2MM | +11% |
Gross Profit | 510.7MM | - |
Cost Of Revenue | 135.5MM | +9% |
Operating Income | 14.2MM | -45% |
Operating Expenses | 496.5MM | - |
Net Income | 20.4MM | -50% |
R&D | 206.2MM | +8% |
G&A | 275MM | +23% |
Interest Expense | 6.1MM | +61% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Although the Nasdaq Composite is galloping to record highs, amazing deals among growth stocks can still be uncovered.
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive early results from an investigator-sponsored Phase 2 study of VOXZOGO® (vosoritide) in children with hypochondroplasia, will be presented at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Toronto, Canada, March 12-16, 2024. Researchers will also present data from Phase 2 and Phase 3 studies of the medicine in children with achondroplasia, including results that demonstrate V
The company is a leader in the global achondroplasia treatment market
Henry Fuchs, President, Worldwide Research & Development at Biomarin Pharmaceutical Inc (NASDAQ:BMRN), sold 35,341 shares of the company on March 5, 2024, according to a recent SEC filing.
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cristin Hubbard has been named executive vice president and chief commercial officer. Ms. Hubbard will assume responsibility for the company's global commercial operations, effective May 20, succeeding Jeff Ajer.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management is scheduled to participate in four upcoming investor conferences in March.
Insightful Analysis of Biomarin's Market Position and Future Prospects
BioMarin Pharmaceutical has received a subpoena from the U.S. Department of Justice seeking information about the company's sponsored testing programs related to two treatments, the therapy maker said in a filing on Monday. The DOJ has asked the company to submit certain documents related to the sponsored testing of its therapies Vimizim and Naglazyme, BioMarin said. "We have produced documents in response to the subpoena and are cooperating fully, but there is no assurance that such sponsored...
BioMarin Pharmaceutical ( NASDAQ:BMRN ) Full Year 2023 Results Key Financial Results Revenue: US$2.42b (up 15% from FY...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2023 Earnings Call Transcript February 22, 2024 BioMarin Pharmaceutical Inc. misses on earnings expectations. Reported EPS is $0.18 EPS, expectations were $0.44. BMRN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing […]